ResearcherAzienda Ospedaliero-Universitaria di ModenaActive in the last 2 years
Giulia Grisendi
Matched on ORCID iD 0000-0002-0120-6129; OpenAlex author ID A5068163176. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 9
2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper
Papers 5
- Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. Co-author DOI 10.1016/j.xcrm.2024.101685↗
- TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. Last author PMID 34659901↗
- Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. First author DOI 10.1038/s41598-018-37433-6↗
- MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Co-author DOI 10.7150/thno.27576↗
- Surrounding pancreatic adenocarcinoma by killer mesenchymal stromal/stem cells. First author DOI 10.1089/hum.2014.039↗
Closest collaborators
The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Carlotta Spano · 5 shared papers, 2014–2024 · strength 0.46
- Paper Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. DOI 10.1016/j.xcrm.2024.101685↗
- Paper TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. PMID 34659901↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Massimo Dominici · 5 shared papers, 2014–2024 · strength 0.46
- Paper Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma. DOI 10.1016/j.xcrm.2024.101685↗
- Paper TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. PMID 34659901↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Andrea Spallanzani · 2 shared papers, 2021–2024 · strength 0.26
- Massimiliano Dall’Ora · 2 shared papers, 2021–2024 · strength 0.26
- Giulia Rovesti · 3 shared papers, 2019–2021 · strength 0.25
- Paper TRAIL receptors are expressed in both malignant and stromal cells in pancreatic ductal adenocarcinoma. PMID 34659901↗
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Paper Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. DOI 10.1038/s41598-018-37433-6↗
- Giulia Golinelli · 3 shared papers, 2014–2019 · strength 0.21
- Paper MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. DOI 10.7150/thno.27576↗
- Paper Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. DOI 10.1038/s41598-018-37433-6↗
- Paper Surrounding pancreatic adenocarcinoma by killer mesenchymal stromal/stem cells. DOI 10.1089/hum.2014.039↗
- Filippo Rossignoli · 2 shared papers, 2019 · strength 0.14
- Giulia Orsi · 2 shared papers, 2019 · strength 0.14
- Stefano Cascinu · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.